Literature DB >> 19535650

FDA approves oral vasopressin antagonist.

Cheryl A Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19535650     DOI： 10.2146/news090054

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

Authors:  Susan E Shoaf; Patricia Bricmont; Suresh Mallikaarjun
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 2.  Arginine vasopressin as a target in the treatment of acute heart failure.

Authors:  Nisha A Gilotra; Stuart D Russell
Journal:  World J Cardiol       Date:  2014-12-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.